January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 


Cambridge Healthtech Institute’s
CHO Cells
Engineering the Process from -Omics to Production
January 21-22, 2015

To meet the huge demand for recombinant proteins, advances in CHO cell culture technology continue to significantly improve production. This achievement is due to progress in both engineering stable and transient cell lines as well as optimizing the cell culture process. When both are accomplished, higher-production titers and better product quality result. The CHO Cells conference gathers cell culture specialists and cell line engineers to explore the latest data, tools and strategies for improving biotherapeutic protein production, expression and product quality.

Day 1 | Day 2 | Download Brochure | Speaker Biographies 

Final Agenda 


1:00 pm Conference Registration

Improving Production and Product Quality

2:00 Chairperson’s Remarks

Jie Chen, Ph.D., Professor, Electrical and Chemical Engineering, University of Alberta, Edmonton

Featured Presentation

2:05 A Novel Approach to Controlling Cell Growth and Improving Specific Productivity and Product Quality in CHO Cell Cultures

ZhimeiDuZhimei Du, Ph.D., Principal Scientist, Cell Culture Development & Manufacturing, Teva Pharmaceuticals USA

We identified a novel approach which can control cell growth and improve specific productivity, as well as product quality simultaneously. Results demonstrate that the cell proliferation is consistently controlled in all recombinant cell lines throughout the production processes with specific productivities increased to as much as 110 pg/cell/day. Additionally, glycan processing is improved by decreasing high mannose and increasing mature G1 and G2 glycoforms. Molecular mechanisms of the related signaling pathways have been studied and will be discussed.

2:35 Increasing Monoclonal Antibody Production Using Low-Intensity Pulsed Ultrasound

JieChenJie Chen, Ph.D., Professor, Electrical and Computer Engineering, University of Alberta, Edmonton

The clinical and commercial success of monoclonal antibodies has led to the need for large-scale production in mammalian cell culture. Our low-intensity pulsed ultrasound (the claims of U.S. patent were allowed) increases production of antibodies in both hybridomas and CHO cells by stimulating the cells. Up to 60% increase in antibody production in hybridoma cells, and up to 25% increase in CHO cells have been achieved within a few days of stimulation.

3:05 Development of Innovative Processes for Expression of Monoclonal Antibodies

Goel_AmitaAmita Goel, MS, CEO, Celltheon

Robust and reproducible processes are required to generate high quality monoclonal antibodies that can accelerate into the clinic.  To meet these demands Celltheon has developed CHO based SMART Expression System and SMART Bioprocessing Technology ™ that has generated high producing stable GMP manufacturing cell lines and processes that increase titers ~6-20 fold, increase yield, product quality and reduce time lines.  


Icosagen3:35 A Stable Episomal Expression System for Protein Production

Meelis Kadaja, Ph.D., CSO, Icosagen Cell Factory

We have developed a novel technology to stably maintain expression vectors in dividing mammalian cells. This enables the quick production of recombinant proteins in gram quantities as well as the ability to tailor the system to improve the quality of each protein. Our system is scalable and suitable for cell bank generation and recombinant antibody production. 

4:05 Refreshment Break

4:30 Plenary Keynote Session

From Yeast to the Brain: Advances in Proteomics (More Details >>

John YatesJohn R. Yates, Ph.D., Ernest W. Hahn Professor, Chemical Physiology and Molecular and Cellular Neurobiology, The Scripps Research Institute


5:30-7:00 Reception in the Exhibit Hall with Poster Viewing

Day 1 | Day 2 | Download Brochure | Speaker Biographies